June 5, 2017 Pertuzumab improved invasive disease–free survival (IDFS) in patients with HER2-positive, early-stage breast cancer when added to chemotherapy and trastuzumab, Gunter von Minckwitz, MD, PhD, of the German Breast Group Research Institute, in Germany, said during the Breast Cancer—Local/Regional/Adjuvant Oral Abstract Session held June 5 (Abstract LBA500). The APHINITY study randomly assigned...
Pro zobrazení tohoto obsahu je třeba být přihlášen.